Biotech veteran Gail Maderis retires on high note as Antiva Biosciences raises $53M to tackle HPV

She came to the Bay Area from Genzyme Corp. 20 years ago to lead Five Prime Therapeutics. She retires with another early-stage company looking to help women — and men — overcome potentially deadly HPV infections.